Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)Benzinga • 02/23/24
Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)Benzinga • 01/16/24
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)GlobeNewsWire • 12/05/23
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)GlobeNewsWire • 11/27/23
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/15/23
GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune DiseasesGlobeNewsWire • 10/31/23
GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung ConferenceGlobeNewsWire • 10/19/23
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease ProgressionGlobeNewsWire • 10/17/23
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO ConferenceGlobeNewsWire • 10/11/23
GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic ConditionsGlobeNewsWire • 10/05/23
September Is Pulmonary Fibrosis Awareness Month: Here's What One Company Is Doing To Develop A Treatment For This Deadly DiseaseAccesswire • 09/29/23
GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/06/23
IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis - Could GRI-0621 Be The Solution?Accesswire • 09/01/23
GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And LupusAccesswire • 08/25/23
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIRGlobeNewsWire • 08/23/23
JTC Team Announces the Launch of the Virtual Investor "What This Means" On Demand Video SeriesAccesswire • 08/16/23
GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/14/23
GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal ModelsGlobeNewsWire • 08/07/23
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight EventGlobeNewsWire • 07/24/23
GRI Bio, Inc. (NASDAQ: GRI) to Participate in the Virtual Investor Summer Spotlight SeriesGlobeNewsWire • 07/05/23